Updated Jul 16, 2026
Garner Ebun is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $1.98M.

Ebun Garner serves as General Counsel and Corporate Secretary for Erasca, Inc. as of the most recent SEC filing dated 2026-01-09, overseeing the company’s legal affairs, corporate governance, and securities compliance. In this role, Garner supports regulatory disclosures, board communications, and strategic corporate activities for the clinical-stage oncology company focused on RAS/MAPK pathway-driven cancers.
| Role | Insider |
|---|---|
| Notability | 45/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-03 | ERAS | Erasca, Inc. | S — Open-market sale [10b5-1] | 80.0K | $16.40 | $1.31M |
| 2026-04-03 | ERAS | Erasca, Inc. | M — Option exercise [10b5-1] | 80.0K | $1.70 | $136K |
| 2026-01-09 | ERAS | Erasca, Inc. | S — Open-market sale [10b5-1] | 120.0K | $5.59 | $671K |
| 2026-01-09 | ERAS | Erasca, Inc. | M — Option exercise [10b5-1] | 120.0K | $1.70 | $204K |
| 2026-01-09 | ERAS | Erasca, Inc. | A — Grant or award [10b5-1] | 3.9K | $1.19 | $5K |
Ebun Garner serves as General Counsel and Corporate Secretary for Erasca, Inc. as of the most recent SEC filing dated 2026-01-09, overseeing the company’s legal affairs, corporate governance, and securities compliance. In this role, Garner supports regulatory disclosures, board communications, and strategic corporate activities for the clinical-stage oncology company focused on…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($1.98M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Garner Ebun profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.